首页
期刊
会议
丛书
课程
数据
知识
期刊论文详细信息
返回上一页
Secukinumab for ankylosing spondylitis Authors' reply
Letter
关键词:
DOUBLE-BLIND
;
PSORIASIS
;
ANTIBODY
;
EFFICACY
;
SAFETY
;
DOI : 10.1016/S0140-6736(14)60399-8
来源:
SCIE
【 授权许可】
Free
文献评价指标
下载次数:0次
浏览次数:0次
推荐资源列表
期刊论文
Targeted anticytokine therapy in patients with chronic heart failure - Results of the Randomized Etanercept Worldwide evALuation (RENEWAL)
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease